Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials
– Seventure Partners and Novartis Pharmaceuticals join as new investors
– Transformative treatment for millions of children with myopia
Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the round and was joined by Novartis Pharmaceuticals and the Company´s existing shareholders such as Boehringer Ingelheim Venture Fund and Ababax Health, significantly broadening the Company’s shareholder base of leading international life science investors.